Abstract:Ghrelin is the only known orexigenic gut hormone, and its synthesis, secretion and degradation are affected by different metabolic statuses. This meta-analysis aimed to investigate the potential differences in plasma acyl ghrelin (AG) and des-acyl ghrelin (DAG) concentrations between normal weight and obese adults. Systematic literature searches of PubMed, Embase and Web of Science through October 2021 were conducted for articles reporting AG or DAG levels in obesity and normal weight, and 34 studies with 1863 participants who met the eligibility criteria were identified. Standardized mean differences (SMDs) with 95% confidence intervals (CIs) were calculated to evaluate group differences in circulating AG and DAG levels. Pooled effect size showed significantly lower levels of baseline AG (SMD: − 0.85; 95% CI: − 1.13 to − 0.57; P SMD < 0.001) and DAG (SMD: − 1.06; 95% CI: − 1.43 to − 0.69; P SMD < 0.001) in obese groups compared with healthy controls, and similar results were observed when subgroup analyses were stratified by the assay technique or storage procedure. Postprandial AG levels in obese subjects were significantly lower than those in controls when stratified by different time points (SMD 30 min : − 0.85, 95% CI: − 1.18 to − 0.53, P SMD < 0.001; SMD 60 min : − 1.00, 95% CI: − 1.37 to − 0.63, P SMD < 0.001; SMD 120 min : − 1.21, 95% CI: − 1.59 to − 0.83, P SMD < 0.001). In healthy subjects, a postprandial decline in AG was observed at 120 min (SMD: − 0.42; 95% CI: − 0.77 to − 0.06; P SMD = 0.021) but not in obese subjects (SMD: − 0.28; 95% CI: − 0.60 to 0.03; P SMD = 0.074). The mean change in AG concentration was similar in both the obese and lean health groups at each time point (ΔSMD 30min : 0.31, 95% CI: − 0.35 to 0.97, P SMD = 0.359; ΔSMD 60min : 0.17, 95% CI: − 0.12 to 0.46, P SMD = 0.246; ΔSMD 120min : 0.21, 95% CI: − 0.13 to 0.54, P SMD = 0.224). This meta-analysis strengthens the clinical evidence supporting the following: lower baseline levels of circulating AG and DAG in obese individuals; declines in postprandial circulating AG levels, both for the healthy and obese individuals; a shorter duration of AG suppression in obese subjects after meal intake. These conclusions have significance for follow-up studies to elucidate the role of various ghrelin forms in energy homeostasis.

The effect of exogenous glucagon on circulating amino acids in individuals with and without type 2 diabetes and obesity

Hyperglucagonaemia and amino acid alterations in individuals with type 2 diabetes and non-alcoholic fatty liver disease

Circulating Acyl and Des-Acyl Ghrelin Levels in Obese Adults: a Systematic Review and Meta-Analysis

Evidence of a liver-alpha cell axis in humans: hepatic insulin resistance attenuates relationship between fasting plasma glucagon and glucagonotropic amino acids

198-OR: The Stimulatory Effect of Glucagon on Insulin Secretion Is Glucose Dependent in Healthy Human Subjects

High Doses of Exogenous Glucagon Stimulate Insulin Secretion and Reduce Insulin Clearance in Healthy Humans

Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study

Effects of Acute Insulin Withdrawal and Administration on Plasma Glucagon Responses to Intravenous Arginine in Insulin-dependent Diabetic Subjects

Determinants of plasma levels of proglucagon and the metabolic impact of glucagon receptor signalling: a UK Biobank study

Comparable glucagon-stimulated amino acid suppression in individuals with and without hepatic steatosis or steatohepatitis

Revisiting the role of glucagon in health, diabetes mellitus and other metabolic diseases

Elevations in plasma glucagon are associated with reduced insulin clearance after ingestion of a mixed-macronutrient meal in people with and without type 2 diabetes

Alterations in Glucagon Levels and the Glucagon-to-Insulin Ratio in Response to High Dietary Fat or Protein Intake in Healthy Lean Adult Twins: A Post Hoc Analysis

Rise in fasting and dynamic glucagon levels in children and adolescents with obesity is moderate in subjects with impaired fasting glucose but accentuated in subjects with impaired glucose tolerance or type 2 diabetes

The Effect of Short Term Physiological Elevations of Plasma Glucagon Concentration on Plasma Triglyceride Concentration in Normal and Diabetic Man

Glucagon agonism in the treatment of metabolic diseases including type 2 diabetes mellitus and obesity

Effects of Dietary Fat and Protein on Glucoregulatory Hormones in Adolescents and Young Adults With Type 1 Diabetes

Glucagon infusion alters the circulating metabolome and urine amino acid excretion in dogs

Acute peripheral tissue effects of ghrelin on interstitial levels of glucose, glycerol, and lactate: a microdialysis study in healthy human subjects

Mechanisms by Which Glucagon Acutely Stimulates Hepatic Mitochondrial Oxidation and Gluconeogenesis

Dietary Protein Defends Lean Mass and Maintains the Metabolic Benefits of Glucagon Receptor Agonism in Mice